Zymeworks Inc. share price logo

Zymeworks Inc.

NASDAQ: ZYME

Small Cap

$23.14

as on

Zymeworks Inc. Stock Performance

as on June 19, 2026 at 2:16 pm IST

  • Day's Low

    Day's High

    $22.65
    $23.52
    downward going graph

    2.12%

    Downside

    1.64%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $11.51
    $29.75
    downward going graph

    50.26%

    Downside

    28.57%

    Upside

    downward going graph

Zymeworks Inc. share price movements today

Previous Close
$23.14
Open
$23.49
Volume
456.6K
Day's Low - High
$22.65 - $23.52
52 Week Low - High
$11.51 - $29.75

Zymeworks Inc. Historical Returns

1 Month Return
-5.16 %
3 Month Return
-3.16 %
1 Year Return
+ 83.21 %
3 Year Return
+ 184.98 %
5 Year Return
-36.17 %

Zymeworks Inc. Stock Fundamentals & Key Indicators

Check Zymeworks Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$1.7B

EPS (TTM)

1.2643

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-107.8M

Revenue (TTM)

81.3M

Profit Margin

-126.33%

Return On Equity TTM

-42.02%

Zymeworks Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Zymeworks Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Zymeworks Inc. image
Zymeworks Inc.
BUY$1.7B-36.17%NA-126.33%NA
Alnylam Pharmaceuticals Inc. image
Alnylam Pharmaceuticals Inc.
BUY$37.7B57.21%71.2112.55%NA
Vertex Pharmaceuticals Inc. image
Vertex Pharmaceuticals Inc.
BUY$116.5B140.42%27.2235.51%NA
Regeneron Pharmaceuticals Inc. image
Regeneron Pharmaceuticals Inc.
BUY$63.7B13.39%14.8529.65%0.58%

Stock Returns calculator for Zymeworks Inc. Stock including INR - Dollar returns

The Zymeworks Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

Zymeworks Inc. investment value today

Current value as on today

₹1,98,974

Returns

₹98,974

(+98.97%)

Returns from Zymeworks Inc. Stock

₹83,215 (+83.21%)

Dollar Impact

₹15,759 (+15.76%)

Analyst Recommendation on Zymeworks Inc. Stock

Based on 14 analysts

BUY

71.43%

Buy

28.57%

Hold

0.00%

Sell

Based on 14 analysts, 71.43% of analysts recommend a 'BUY' rating for Zymeworks Inc.. Average target price of $39.23

Zymeworks Inc. Share Price Target

Get share price movements and forecasts by analysts on Zymeworks Inc..

What analysts predicted

41.01%UPSIDE

Target Price

$39.23

Current Price

$23.14

Analyzed by

14 Analysts

Target

$39.23

Zymeworks Inc. target price $39.23, a slight upside of 41.01% compared to current price of $23.14. According to 14 analysts rating.

Indian Investors' Interest in Zymeworks Inc. Stock

Search interest for Zymeworks Inc. Stock has decreased by -54% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-54% versus previous 30 day period

Zymeworks Inc. Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Total Revenue
16
10
19
16
31
27
48
27
2
2
Gross Profit
16
10
19
16
31
27
48
27
0
0
Operating Income
-23
-37
-42
-34
-22
-25
0
-22
-44
-47
EBITDA
-20
-20
-23
-31
-18
-22
2
-15
-39
-41
Interest Expense
7
-
-
-
-
-
-
-
-
2
Depreciation
3
2
2
2
3
3
3
2
2
2
Income Before Tax
-19
-31
-37
-29
-17
-22
2
-18
-41
-46
Income Tax Expense
-4
0
0
0
5
0
0
1
0
-2
Net Income
-14
-31
-37
-29
-23
-22
2
-19
-41
-44
Net Profit Margin
-85.56%
-315.58%
-195.84%
-186.56%
-75.75%
-83.50%
4.76%
-70.99%
-1638.53%
-1833.97%

Zymeworks Inc. Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
11
51
53
29
38
26
412
76
76
105
Gross Profit
-24
10
53
-87
38
26
412
-66
76
105
Operating Income
-37
-8
-33
-151
-187
-215
130
-138
-137
-92
EBITDA
-36
-6
-29
-148
-177
-206
142
-120
-108
-68
Interest Expense
0
1
0
11
17
12
3
-
-
-
Depreciation
-
2
3
7
10
12
12
17
11
11
Income Before Tax
-38
-9
-34
-144
-180
-212
135
-119
-116
-79
Income Tax Expense
-5
0
2
0
0
0
10
0
6
1
Net Income
-33
-10
-36
-145
-180
-211
124
-118
-122
-81
Net Profit Margin
-307.10%
-20.10%
-68.95%
-492.27%
-463.54%
-794.01%
30.14%
-156.13%
-160.80%
-76.56%

Zymeworks Inc. Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Net Income
-31
-37
-29
-23
-22
2
-19
-41
-44
Operating Cash Flow
-37
-24
-5
-41
-3
12
-31
-9
-45
Investing Cash Flow
-7
-19
72
-6
12
8
0
5
69
Financing Cash Flow
2
1
-14
-8
1
1
-2
-18
178
Change in Cash
-42
-43
51
-56
10
22
-33
-23
203

Zymeworks Inc. Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-10
-36
-145
-180
-211
124
-118
-122
-81
Operating Cash Flow
0
24
-81
-151
-192
144
-118
-110
-33
Investing Cash Flow
-30
-109
-25
-43
144
-53
-207
38
26
Financing Cash Flow
49
91
193
308
8
108
81
-20
-18
Change in Cash
19
6
86
113
-40
199
-243
-91
-24

Global Institutional Holdings in Zymeworks Inc.

Funds
Holdings
BNP Paribas Investment Partners SA
2.59%
Vanguard Capital Management, LLC
2.32%
Dimensional Fund Advisors, Inc.
1.55%
Citadel Advisors Llc
1.56%
Blackstone Inc
2.18%
See all

Zymeworks Inc. News & Key Events

  • img

    Today's Timeline - 02 March

    Mon, 04:40 PM

    -

    Zymeworks secures $250 million royalty funding from Royalty Pharma, retaining 70% of royalties on Ziihera sales during repayment.

Insights on Zymeworks Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 years, ZYME stock has moved up by 176.1%

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, ZYME has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, ZYME has outperformed top 5 stocks with highest market-cap in its industry

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 4 quarters, 2.31M → -44.16M (in $), with an average decrease of 354.5% per quarter

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 4 quarters, 48.72M → 2.40M (in $), with an average decrease of 46.2% per quarter

About Zymeworks Inc.

Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidates include Ziihera (zanidatamab-hrii), a bispecific antibody targeting HER2-expressing tumors; zanidatamab for the treatment of neoadjuvant populations, breast cancer, and other HER2-expressing cancers; Pasritamig, a bispecific T cell engager targeting human kallikrein 2 for the treatment monotherapy and castration resistant prostate cancer; ZW191, a clinical- antibody-drug conjugates (ADC) that targets folate receptor alpha expressing tumors, including ovarian, endometrial, and non-small cell lung cancers; ZW251, a clinical-stage ADC molecule for the treatment of glypican 3 expressing hepatocellular carcinoma; ZW220, an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer; ZW209, a novel TriTCE targeting Delta-like ligand 3 -expressing tumor cells for the treatment of solid tumors; and ZW1528, a bispecific molecule to treat chronic obstructive pulmonary disease. It has strategic partnerships and collaborations with Jazz Pharmaceuticals plc; Bristol- Myers Squibb company; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Merck Sharp & Dohme Research GmbH; and Janssen Biotech, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
OrganisationZymeworks Inc.
Headquarters108 Patriot Drive, Middletown, DE, United States, 19709
IndustryBiotechnology
CEOMr. Kenneth H. Galbraith C.A.
E-voting on sharesClick here to vote

Key Management of Zymeworks Inc.

Name

Title

Ms. Bijal Desai M.B.A.

Senior Vice President of Finance

Mr. Kenneth H. Galbraith C.A.

Chairman of the Board, CEO & President

Mr. Mark Hollywood

Executive VP & Chief Operating Officer

Ms. Shrinal Inamdar

VP of Investor Relations

Mr. Paul R. Schneider

Executive VP & General Counsel

Ms. Diana Papove B.Com.

Vice President of Corporate Communications

Ms. Laura O'Connor

Senior VP & Chief Human Resources Officer

Dr. Paul A. Moore Ph.D.

Chief Scientific Officer

Mr. Scott Platshon

Executive VP & Chief Business Officer

Dr. Lindsey Foulkes B.Sc., Ph.D.

SVP of Corporate Development & Strategy

FAQs

What is Zymeworks Inc. share price today?

Zymeworks Inc. share price today is $23.14 as on at the close of the market. Zymeworks Inc. share today touched a day high of $23.52 and a low of $22.65.

What is the 52 week high and 52 week low for Zymeworks Inc. share?

Zymeworks Inc. share touched a 52 week high of $29.75 on and a 52 week low of $11.51 on . Zymeworks Inc. stock price today i.e. is closed at $23.14,which is 22.22% down from its 52 week high and 101.04% up from its 52 week low.

What is Zymeworks Inc.'s market capitalisation today?

Zymeworks Inc. market capitalisation is $0.00T as on .

How to invest in Zymeworks Inc. Stock (ZYME) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Zymeworks Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Zymeworks Inc. Shares that will get you 0.0648 shares as per Zymeworks Inc. share price of $23.14 per share as on June 19, 2026 at 8:46 am IST.

What is the minimum amount required to buy Zymeworks Inc. Stock (ZYME) from India?

Indian investors can start investing in Zymeworks Inc. (ZYME) shares with as little as ₹94.31 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹943.10 in Zymeworks Inc. stock (as per the Rupee-Dollar exchange rate as on ). Based on Zymeworks Inc. share’s latest price of $23.14 as on June 19, 2026 at 8:46 am IST, you will get 0.4322 shares of Zymeworks Inc.. Learn more about fractional shares .

What are the returns that Zymeworks Inc. has given to Indian investors in the last 5 years?

Zymeworks Inc. stock has given -36.17% share price returns and 27.56% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?